scholarly journals Association between Sarcopenia and Physical Function among Preoperative Lung Cancer Patients

2020 ◽  
Vol 10 (4) ◽  
pp. 166
Author(s):  
Sunga Kong ◽  
Sumin Shin ◽  
Jae Kyung Lee ◽  
Genehee Lee ◽  
Danbee Kang ◽  
...  

We aimed to investigate the prevalence of sarcopenia using new diagnostic criteria and association of sarcopenia with cardiopulmonary function and physical activity (PA) in preoperative lung cancer patients. The data of 614 patients were obtained from the CATCH-LUNG cohort study. Patients were classified into three groups—normal (n = 520), pre-sarcopenia (n = 60, low skeletal muscle mass index only), and sarcopenia (n = 34, low SMI and strength). Cardiopulmonary function was measured using the 6-min walk test (6MWT), and PA was objectively measured using a wearable device. The adjusted odds ratio (aOR) for a <400-m distance in 6MWT was 3.52 (95% confidence interval (CI) 1.34–9.21) and 6.63 (95% CI 2.25–19.60) in the pre-sarcopenia and sarcopenia groups, respectively, compared to that in the normal group. The aOR (95% CI) for <5000 steps/day was 1.64 (0.65–4.16) and 4.20 (1.55–11.38) in the pre-sarcopenia and sarcopenia groups, respectively, compared to that in the normal group. In conclusion, the prevalence of pre-sarcopenia and sarcopenia was 9.8% and 5.5%, respectively, among preoperative lung cancer patients. Cardiopulmonary function and physical activity were significantly lower in the pre-sarcopenia and sarcopenia groups than in the normal group. Patients with sarcopenia had more robust findings, suggesting the importance of muscle strength and mass.

Author(s):  
Lucía Vaquero ◽  
Antoni Rodríguez‐Fornells ◽  
María Ángeles Pera‐Jambrina ◽  
Jordi Bruna ◽  
Marta Simó

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 9507-9507 ◽  
Author(s):  
Janette L. Vardy ◽  
Melanie Bell ◽  
Hidde van der Ploeg ◽  
Jane Turner ◽  
Michael Kabourakis ◽  
...  

2021 ◽  
Vol 2 (12) ◽  
pp. 1274-1282
Author(s):  
Somayeh Taghvaei ◽  
Leila Saremi ◽  
Majid Motovali-bashi

Background: Lung cancer is the most common cancer with 2,206,771 new cases in 2020 in worldwide. MMP9 is a member of matrix metalloproteinase family that is also known as gelatinase B or IV type collagenase (92KD). MMP9 through degrading of Extracellular Matrix (ECM) and releasing of growth factors has fundamental role in the tumorigenesis process. The C -1562 T SNP in the MMP9 promoter increases MMP9 expression and susceptibility to lung cancer. Then, the aim of this present case-control study was to investigate whether genetic variations of the MMP9 gene may constitute markers for lung cancer risk in males and in positive family history people in Iran. Methods: This is a case-control study including 120 lung cancer patients and 100 healthy controls. Polymorphism in the C -1562 T region was genotyped by PCR-RFLP assay. Odds Ratio (ORs) and 95% Confidence Intervals (CIs) were estimated by chi-square test from comparison of genotypes between lung cancer patients and healthy controls, using SPSS version 26.0. T-test and Image J software was also used. Results: The distribution of C-1562T genotype was significantly associated with the risk of lung cancer (Odds Ratio [OR] = 2.56, 95% Confidence Interval [CI] = 0.06-23.82). The further stratification analyses shown that males and patients with positive family history may increase risk of lung cancer. Conclusion: Our results indicated that the MMP9 C -1562 T polymorphism affects risk of lung cancer. In addition, men with T allele (OR = 3.94, CI = 1.47-10`.55) and patients with TT genotype and family history (OR = 2.18, CI = 1.03-4.59) exposure to higher risk of lung cancer.


2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e23158-e23158
Author(s):  
Gilberto Castro ◽  
Alberto Codima ◽  
Willian das Neves ◽  
Ana Paula Souza Borges

e23158 Background: The symptoms which burden lung cancer patients contribute to a vicious cycle of physical inactivity as the disease progresses. Some studies have shown that exercise is feasible and safe for this population, and it improves their symptoms and quality of life. However, the current recommendations are non-specific, and little is known about the optimal amount and type of exercise in this scenario. Here we aimed to identify a specific recommendation of physical activity that could work more efficiently, benefiting lung cancer patients, in terms of diminishing their symptom burden and improving quality of life. Methods: A systematic review was undertaken through structured searches on PubMed, Medline, Embase, Scopus, Web of Science and SciELO. The search protocol was registered on the Prospero platform. Rayyan QCRI was used for data extraction and determining eligible studies after a blind screening of titles and abstracts by the three authors. The Physiotherapy Evidence Database (PEDro) scale was used for quality assessment of each eligible trial in regards of risk of bias. Trials which had clear eligibility criteria and a summary score equal or superior than 6 were considered to have low risk of bias, and accepted for full text review. Results: From September/1998 to January/2019, a total amount of 1998 studies were returned from the aforementioned databases, and 17 studies were established to be eligible for quality assessment. All the 17 quality-assessed studies were randomized clinical trials. However, two of them did not clearly report the eligibility criteria and were immediately excluded. Five other studies were considered to have high risk of bias. Therefore, we considered only 10 trials to be fully reviewed, including 843 patients. Only 3 trials found significant improvement in the quality of life after their interventions, and included 243 patients. Two studies associated aerobic exercise and resistance training from 10 to 20 weeks post surgery, while the other studied intervention was Tai Chi for 10 days after each chemotherapy cycle. Conclusions: Evidence from this review suggests that exercise may improve quality of life of lung cancer patients. However, we could not identify an ideal amount nor type of physical activity given the limited available data and the heterogeneity of methods. Further studies are warranted.


2015 ◽  
Vol 38 (3) ◽  
pp. 215-223 ◽  
Author(s):  
Hui-Mei Chen ◽  
Yu-Chung Wu ◽  
Chun-Ming Tsai ◽  
Jann-Inn Tzeng ◽  
Chia-Chin Lin

Cancer ◽  
2008 ◽  
Vol 113 (12) ◽  
pp. 3430-3439 ◽  
Author(s):  
Lee W. Jones ◽  
Neil D. Eves ◽  
Bercedis L. Peterson ◽  
Jennifer Garst ◽  
Jeffrey Crawford ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document